• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

仅接受手术治疗的分化良好型胎儿肝母细胞瘤患儿的结局:来自儿童肿瘤组试验 AHEP0731 的报告。

Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: Report from Children's Oncology Group Trial, AHEP0731.

机构信息

Baylor College of Medicine, Texas Children's Hospital, 6701 Fannin, Houston, TX 77030, United States.

Primary Children's Hospital, University of Utah, 100N. Mario Capecchi Dr., Salt Lake City, UT 84113, United States.

出版信息

J Pediatr Surg. 2022 Oct;57(10):251-256. doi: 10.1016/j.jpedsurg.2022.05.022. Epub 2022 Jun 9.

DOI:10.1016/j.jpedsurg.2022.05.022
PMID:35810020
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9474653/
Abstract

BACKGROUND

Hepatoblastoma (HB) requires surgical resection for cure, but only 20-30% of patients have resectable disease at diagnosis. Patients who undergo partial hepatectomy at diagnosis have historically received 4-6 cycles of adjuvant chemotherapy; however, those with 100% well-differentiated fetal histology (WDF) have been observed to have excellent outcomes when treated with surgery alone.

PATIENTS AND METHODS

Patients on the Children's Oncology Group non randomized, multicenter phase III study, AHEP0731, were stratified based on Evan's stage, tumor histology, and serum alpha-fetoprotein level at diagnosis. Patients were eligible for the very low risk stratum of surgery and observation if they had a complete resection at diagnosis and rapid central histologic review demonstrated HB with 100% WDF histology.

RESULTS

A total of 8 eligible patients were enrolled on study between September 14, 2009 and May 28, 2014. Outcome current to 06/30/2020 was used in this analysis. The median age at enrollment was 22.5 months (range: 8-84 months) and the median AFP at enrollment was 714 ng/ml (range: 18-77,747 ng/mL). With a median follow-up of 6.6 years (range: 3.6-9.8 years), the 5-year event-free (EFS) and overall survival (OS) were both 100%.

CONCLUSION

This report supports that HB with 100% WDF histology completely resected at diagnosis is curable with surgery only. The development of evidence-based surgical guidelines utilizing criteria based on PRETEXT group, vascular involvement (annotation factors), tumor-specific histology and corresponding biology will be crucial for optimizing which patients are candidates for resection at diagnosis followed by observation.

LEVEL OF EVIDENCE

Prognosis study, Level I evidence.

摘要

背景

肝母细胞瘤(HB)需要手术切除才能治愈,但只有 20-30%的患者在诊断时具有可切除的疾病。在诊断时接受部分肝切除术的患者历史上接受了 4-6 个周期的辅助化疗;然而,当仅用手术治疗时,具有 100%良好分化的胎儿组织学(WDF)的患者观察到具有极好的结果。

患者和方法

在儿童肿瘤学组非随机、多中心 III 期研究 AHEP0731 中,根据 Evan 分期、肿瘤组织学和诊断时的血清甲胎蛋白(AFP)水平对患者进行分层。如果患者在诊断时进行了完全切除,并且快速中心组织学检查显示 HB 具有 100% WDF 组织学,则有资格在手术和观察中进入非常低风险分层。

结果

共有 8 名符合条件的患者于 2009 年 9 月 14 日至 2014 年 5 月 28 日入组研究。本分析采用截至 2020 年 6 月 30 日的结果。入组时的中位年龄为 22.5 个月(范围:8-84 个月),入组时 AFP 的中位值为 714ng/ml(范围:18-77747ng/ml)。中位随访 6.6 年(范围:3.6-9.8 年),5 年无事件生存(EFS)和总生存(OS)均为 100%。

结论

本报告支持诊断时完全切除的具有 100% WDF 组织学的 HB 仅通过手术即可治愈。利用 PRETEXT 组、血管受累(注释因素)、肿瘤特异性组织学和相应生物学的标准制定基于证据的手术指南对于优化哪些患者适合在诊断时进行切除,然后进行观察至关重要。

证据水平

预后研究,I 级证据。

相似文献

1
Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: Report from Children's Oncology Group Trial, AHEP0731.仅接受手术治疗的分化良好型胎儿肝母细胞瘤患儿的结局:来自儿童肿瘤组试验 AHEP0731 的报告。
J Pediatr Surg. 2022 Oct;57(10):251-256. doi: 10.1016/j.jpedsurg.2022.05.022. Epub 2022 Jun 9.
2
Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial.诊断时切除的肝母细胞瘤患儿的最小辅助化疗(AHEP0731):儿童肿瘤学组、多中心、3 期试验。
Lancet Oncol. 2019 May;20(5):719-727. doi: 10.1016/S1470-2045(18)30895-7. Epub 2019 Apr 8.
3
Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee.小细胞未分化组织学并不影响肝母细胞瘤的预后:来自儿童肿瘤组(COG)AHEP0731 研究委员会的报告。
J Clin Oncol. 2022 Feb 10;40(5):459-467. doi: 10.1200/JCO.21.00803. Epub 2021 Dec 7.
4
Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee.高危肝母细胞瘤的 upfront 窗口长春新碱/伊立替康治疗:儿童肿瘤学组 AHEP0731 研究委员会的报告
Cancer. 2017 Jun 15;123(12):2360-2367. doi: 10.1002/cncr.30591. Epub 2017 Feb 17.
5
Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group.对于具有纯胎儿组织学特征的肝母细胞瘤患儿,完整的手术切除是治愈的关键:来自儿童肿瘤协作组的报告。
J Clin Oncol. 2011 Aug 20;29(24):3301-6. doi: 10.1200/JCO.2010.29.3837. Epub 2011 Jul 18.
6
Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.儿童肿瘤学组AHEP0731方案(儿童各期肝母细胞瘤的治疗)治疗的肝母细胞瘤患儿肺转移特征:来自儿童肿瘤学组的报告
J Clin Oncol. 2017 Oct 20;35(30):3465-3473. doi: 10.1200/JCO.2017.73.5654. Epub 2017 Sep 11.
7
Vincristine/irinotecan/temsirolimus upfront window treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 Study Committee.长春新碱/伊立替康/替西罗莫司一线治疗高危肝母细胞瘤:来自儿童肿瘤学组 AHEP0731 研究委员会的报告。
Pediatr Blood Cancer. 2023 Jul;70(7):e30365. doi: 10.1002/pbc.30365. Epub 2023 Apr 19.
8
Treatment outcomes and prognostic factors in children with hepatoblastoma using a risk-stratified approach.采用风险分层方法治疗肝母细胞瘤患儿的治疗结果和预后因素。
Pediatr Blood Cancer. 2023 Jul;70(7):e30302. doi: 10.1002/pbc.30302. Epub 2023 Apr 12.
9
[Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].[高风险和标准风险肝母细胞瘤的差异化治疗方案——德国肝脏肿瘤研究HB99的中期报告]
Klin Padiatr. 2003 May-Jun;215(3):159-65. doi: 10.1055/s-2003-39375.
10
Microscopically positive resection margin after hepatoblastoma resection: what is the impact on prognosis? A Childhood Liver Tumours Strategy Group (SIOPEL) report.肝母细胞瘤切除术后显微镜下阳性切缘:对预后有何影响?儿童肝脏肿瘤策略组(SIOPEL)报告。
Eur J Cancer. 2019 Jan;106:126-132. doi: 10.1016/j.ejca.2018.10.013. Epub 2018 Dec 5.

引用本文的文献

1
Oncogenic Role of Aberrant EZH2 in Hepatoblastoma.异常EZH2在肝母细胞瘤中的致癌作用。
bioRxiv. 2025 Aug 1:2025.07.30.667506. doi: 10.1101/2025.07.30.667506.
2
From preneoplastic lesion to heterogenous tumor: recent insights into hepatoblastoma biology and therapeutic opportunities.从癌前病变到异质性肿瘤:肝母细胞瘤生物学及治疗机遇的最新见解
Mol Cancer. 2025 Jul 19;24(1):198. doi: 10.1186/s12943-025-02405-8.
3
Hepatoblastoma.肝母细胞瘤
Nat Rev Dis Primers. 2025 May 22;11(1):36. doi: 10.1038/s41572-025-00620-7.
4
Divergent WNT signaling and drug sensitivity profiles within hepatoblastoma tumors and organoids.肝母细胞瘤肿瘤和类器官中存在分歧的 WNT 信号和药物敏感性特征。
Nat Commun. 2024 Nov 20;15(1):8576. doi: 10.1038/s41467-024-52757-w.
5
Upfront or delayed surgery in resectable hepatoblastoma: analysis from the children's hepatic tumors international collaboration database.可切除性肝母细胞瘤的 upfront 或延迟手术:来自儿童肝脏肿瘤国际协作数据库的分析。
EClinicalMedicine. 2024 Sep 9;76:102811. doi: 10.1016/j.eclinm.2024.102811. eCollection 2024 Oct.
6
Prognostic value of systemic inflammation response index in hepatoblastoma patients receiving preoperative neoadjuvant chemotherapy.全身炎症反应指数在接受术前新辅助化疗的肝母细胞瘤患者中的预后价值
Front Oncol. 2023 Oct 13;13:1276175. doi: 10.3389/fonc.2023.1276175. eCollection 2023.
7
Children's Oncology Group's 2023 blueprint for research: Liver tumors.儿童肿瘤学组 2023 年研究蓝图:肝脏肿瘤。
Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30576. doi: 10.1002/pbc.30576. Epub 2023 Jul 26.

本文引用的文献

1
Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial.诊断时切除的肝母细胞瘤患儿的最小辅助化疗(AHEP0731):儿童肿瘤学组、多中心、3 期试验。
Lancet Oncol. 2019 May;20(5):719-727. doi: 10.1016/S1470-2045(18)30895-7. Epub 2019 Apr 8.
2
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.硫代硫酸钠预防顺铂所致耳聋的研究
N Engl J Med. 2018 Jun 21;378(25):2376-2385. doi: 10.1056/NEJMoa1801109.
3
Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups.肝癌的基因组分析确定了不同的分子和预后亚组。
Hepatology. 2017 Jan;65(1):104-121. doi: 10.1002/hep.28888. Epub 2016 Nov 29.
4
Impact of postoperative complications on overall survival of patients with hepatoblastoma.术后并发症对肝母细胞瘤患者总生存期的影响。
Pediatr Blood Cancer. 2015 Jan;62(1):24-8. doi: 10.1002/pbc.25240. Epub 2014 Sep 22.
5
Current chemotherapeutic approaches for hepatoblastoma.当前用于肝母细胞瘤的化疗方法。
Int J Clin Oncol. 2013 Dec;18(6):955-61. doi: 10.1007/s10147-013-0616-8. Epub 2013 Sep 20.
6
Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium.迈向国际小儿肝肿瘤共识分类:洛杉矶 COG 肝肿瘤研讨会会议记录。
Mod Pathol. 2014 Mar;27(3):472-91. doi: 10.1038/modpathol.2013.80. Epub 2013 Sep 6.
7
Surgical treatment of hepatoblastoma.肝母细胞瘤的外科治疗。
Pediatr Blood Cancer. 2012 Nov;59(5):800-8. doi: 10.1002/pbc.24220. Epub 2012 Aug 8.
8
Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies.新诊断的肝母细胞瘤的化疗方法:过去、现在和未来的策略。
Pediatr Blood Cancer. 2012 Nov;59(5):809-12. doi: 10.1002/pbc.24219. Epub 2012 May 30.
9
Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group.对于具有纯胎儿组织学特征的肝母细胞瘤患儿,完整的手术切除是治愈的关键:来自儿童肿瘤协作组的报告。
J Clin Oncol. 2011 Aug 20;29(24):3301-6. doi: 10.1200/JCO.2010.29.3837. Epub 2011 Jul 18.
10
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.顺铂与顺铂加阿霉素治疗标准风险肝母细胞瘤的比较。
N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613.